162 related articles for article (PubMed ID: 38373592)
1. Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects.
Chen Y; Liu C; Fang Y; Chen W; Qiu J; Zhu M; Wei W; Tu J
Biochem Pharmacol; 2024 Apr; 222():116066. PubMed ID: 38373592
[TBL] [Abstract][Full Text] [Related]
2. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
3. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
[TBL] [Abstract][Full Text] [Related]
4. CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines
Ma MT; Badeti S; Chen CH; Kim J; Choudhary A; Honnen B; Reichman C; Calianese D; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
Front Immunol; 2021; 12():652223. PubMed ID: 34367128
[TBL] [Abstract][Full Text] [Related]
5. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.
Christodoulou I; Rahnama R; Ravich JW; Seo J; Zolov SN; Marple AN; Markovitz DM; Bonifant CL
Front Immunol; 2021; 12():763460. PubMed ID: 35003077
[TBL] [Abstract][Full Text] [Related]
8. Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report.
Nilius-Eliliwi V; Mika T; Baraniskin A; Wünnenberg M; Maslova M; Boy C; Klein-Scory S; Schroers R; Vangala D
Front Oncol; 2021; 11():706431. PubMed ID: 34336692
[TBL] [Abstract][Full Text] [Related]
9. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
Meir J; Abid MA; Abid MB
Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.
McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090
[TBL] [Abstract][Full Text] [Related]
11. Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study.
Hensley MK; Bain WG; Jacobs J; Nambulli S; Parikh U; Cillo A; Staines B; Heaps A; Sobolewski MD; Rennick LJ; Macatangay BJC; Klamar-Blain C; Kitsios GD; Methé B; Somasundaram A; Bruno TC; Cardello C; Shan F; Workman C; Ray P; Ray A; Lee J; Sethi R; Schwarzmann WE; Ladinsky MS; Bjorkman PJ; Vignali DA; Duprex WP; Agha ME; Mellors JW; McCormick KD; Morris A; Haidar G
Clin Infect Dis; 2021 Aug; 73(3):e815-e821. PubMed ID: 33507235
[TBL] [Abstract][Full Text] [Related]
12. A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
Xia L; Yuan LZ; Hu YH; Liu JY; Hu GS; Qi RY; Zhang TY; Xiong HL; Zheng ZZ; Lin HW; Zhang JM; Yu C; Zhou M; Ma J; Cheng T; Chen RR; Guan Y; Xia NS; Liu W
Cell Mol Immunol; 2023 Apr; 20(4):351-364. PubMed ID: 36864189
[TBL] [Abstract][Full Text] [Related]
13. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.
Aleissa MM; Little JS; Davey S; Saucier A; Zhou G; Gonzalez-Bocco IH; Crombie JL; Looka A; Baden LR; Issa NC; Hammond SP; Jacobson CA; Sherman AC
Transplant Cell Ther; 2023 Jun; 29(6):398.e1-398.e5. PubMed ID: 36906276
[TBL] [Abstract][Full Text] [Related]
14. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
Wu X; Wang L; Shen L; He L; Tang K
J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches.
Zavvar M; Yahyapoor A; Baghdadi H; Zargaran S; Assadiasl S; Abdolmohammadi K; Hossein Abooei A; Reza Sattarian M; JalaliFarahani M; Zarei N; Farahvash A; Fatahi Y; Deniz G; Zarebavani M; Nicknam MH
Int Immunopharmacol; 2022 Jun; 107():108655. PubMed ID: 35248946
[TBL] [Abstract][Full Text] [Related]
16. Specific Activation of T Cells by an ACE2-Based CAR-Like Receptor upon Recognition of SARS-CoV-2 Spike Protein.
Gonzalez-Garcia P; Muñoz-Miranda JP; Fernandez-Cisnal R; Olvera L; Moares N; Gabucio A; Fernandez-Ponce C; Garcia-Cozar F
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108807
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy.
Xiao X; Chen P; Zhong Y; Luo X; Liu Y; Lu Y; Jin X; Qian W; Han W; Liang A; Liu H
Cancer Med; 2023 Nov; 12(22):20838-20846. PubMed ID: 37962082
[TBL] [Abstract][Full Text] [Related]
18. CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.
Hu Y; Tan Su Yin E; Yang Y; Wu H; Wei G; Su J; Cui Q; Jin A; Yang L; Fu S; Zhou J; Qiu L; Zhang X; Liang A; Jing H; Li Y; Blaise D; Mohty M; Nagler A; Huang H
Curr Res Transl Med; 2020 Aug; 68(3):111-118. PubMed ID: 32620465
[TBL] [Abstract][Full Text] [Related]
19. Current status in cellular-based therapies for prevention and treatment of COVID-19.
Hattab D; Amer MFA; Mohd Gazzali A; Chuah LH; Bakhtiar A
Crit Rev Clin Lab Sci; 2023 Aug; 60(5):321-345. PubMed ID: 36825325
[TBL] [Abstract][Full Text] [Related]
20. Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities.
Nova Z; Zemanek T; Botek N
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
